Abstract | Background: Methods: PubMed, Embase, and Cochrane Library databases were searched for clinical trials that evaluated the serotonin agonist for migraine treatment versus placebo. The main outcomes were to perform dose-response model-based network meta-analysis of different serotonin agonists and to compute the relative risk for paresthesia. In addition, probability of paresthesia among various treatments was estimated by the Surface Under the Cumulative Ranking (SUCRA) method. The R 4.30 and Rev Man 5.3 softwares were used to perform meta-analysis. Results: A total of 30 placebo-controlled clinical trials (29,154 subjects) were included in the study to perform dose-response model-based network meta-analysis to explore the risk of paresthesia with different serotonin agonists versus placebo. The drugs Topiramate 200 mg, Lasmiditan 400 mg, and Zolmitriptan 10 mg showed higher relative risks for paraesthesia as 2.71, 2.2, and 2.42, respectively. However, the SUCRA probabilities of paresthesia for each treatment in the network were higher for Lasmiditan. Conclusions:
|
Authors | Sayed Aliul Hasan Abdi, Shabihul Fatma Sayed, Jamuna Bhaskar |
Journal | Annals of Indian Academy of Neurology
(Ann Indian Acad Neurol)
2022 Jul-Aug
Vol. 25
Issue 4
Pg. 669-675
ISSN: 0972-2327 [Print] India |
PMID | 36211148
(Publication Type: Journal Article)
|
Copyright | Copyright: © 2022 Annals of Indian Academy of Neurology. |